Sectors
NRSN
NeuroSense Therapeutics Ltd.
0.64
1 x 0.64
1 x 0.66
bid
ask
-
0.06
8.57%
01:42 PM
timesize
| Ytd | -16.78% | |
| 1y | -66.84% |
0.63
day range
0.69
0.63
52 week range
2.10
| Open | 0.68 | Prev Close | 0.70 | Low | 0.63 | High | 0.69 | Mkt Cap | 17.27M |
| Vol | 122.91K | Avg Vol | 154.57K | EPS | -0.51 | P/E | -1.36 | Forward P/E | -2.27 |
| Beta | 1.58 | Short Ratio | 2.01 | Inst. Own | 0.97% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-08 | 50-d Avg | 0.76 | 200-d Avg | 0.89 | 1yr Est | 7.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-12-18 | 2024-09 | 0 | -0.11 | N/A | N/A |
| 2024-06-24 | 2024-03 | 0 | -0.35 | N/A | N/A |
| 2024-04-05 | 2023-12 | 0 | -0.16 | N/A | N/A |
| 2023-11-28 | 2023-09 | 0 | 0.1 | N/A | N/A |
| 2023-08-16 | 2023-06 | 0 | -0.44 | N/A | N/A |
| 2023-06-01 | 2023-03 | 0 | -0.33 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-16 | Maxim Group | Downgrade | Buy | Hold |
Profile
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Cantor Fitzgerald, L.P. | 79.49K | 99.37K | 0.34% |
| 2024-09-29 | Xtx Topco Ltd | 46.00K | 57.50K | 0.20% |
| 2024-09-29 | Meitav Investment House Ltd. | 40.00K | 50.00K | 0.17% |
| 2024-09-29 | Citadel Advisors Llc | 34.28K | 42.85K | 0.15% |
| 2024-09-29 | Commonwealth Equity Services, LLC | 12.63K | 15.78K | 0.05% |
| 2024-09-29 | Geode Capital Management, LLC | 11.96K | 14.95K | 0.05% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 11.96K | 14.95K | 0.05% |